Protective effects of mineralocorticoid receptor blockade against neuropathy in experimental diabetic rats

Takata, Hiroyuki; Takeda, Yoshiyu; Zhu, Aoshuang; Cheng, Yuan; Yoneda, Takashi; Demura, Masashi; Yagi, Kunimasa; Yamagishi, Masakazu

doi:10.1111/j.1463-1326.2011.01499.x

Cited by 10 publications

(5 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, our current study observed that the increased renal COX-2 expression in diabetic rats was markedly inhibited by the combined therapy of the spironolactone and candesartan supporting the important protective role of MR blockade in diabetes (Takata et al, 2012).…”

Section: Discussionmentioning

confidence: 84%

Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats

Hofni¹,

El‐Moselhy²,

Taye³

et al. 2014

European Journal of Pharmacology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 84%

Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats

Hofni¹,

El‐Moselhy²,

Taye³

et al. 2014

European Journal of Pharmacology

View full text Add to dashboard Cite

“…212 Spironolactone ameliorates insulin resistance 213 ; and aldosterone contributes to the microvascular complications of diabetes. 214,215 Leptin also plays a central role in immune responses and inflammation. 216 The adipokine stimulates the proliferation of monocytes and their production of proinflammatory cytokines, and it fuels the activation of T cells.…”

Section: Role Of Aldosterone Leptin and Natriuretic Peptides In The mentioning

confidence: 99%

“…Finally, adipocytes are an important source of aldosterone, 209 and obesity is characterized by hyperaldosteronism 210 ; increased levels of aldosterone precede the development of the metabolic syndrome 211 and predict the development of diabetes 212 . Spironolactone ameliorates insulin resistance 213 ; and aldosterone contributes to the microvascular complications of diabetes 214,215 …”

Section: Role Of Aldosterone Natriuretic Peptides and Leptin In The mentioning

confidence: 99%

Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease

Packer

Lam

Lund

et al. 2020

European J of Heart Fail

117

109

View full text Add to dashboard Cite

Accumulating evidence points to the existence of an inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction (HFpEF), which is characterized by biomarkers of inflammation, an expanded epicardial adipose tissue mass, microvascular endothelial dysfunction, normal-to-mildly increased left ventricular volumes and systolic blood pressures, and possibly, altered activity of adipocyte-associated inflammatory mediators. A broad range of adipogenic metabolic and systemic inflammatory disorders-e.g. obesity, diabetes and metabolic syndrome as well as rheumatoid arthritis and psoriasis-can cause this phenotype, independent of the presence of large vessel coronary artery disease. Interestingly, when compared with men, women are both at greater risk of and may suffer greater cardiac consequences from these systemic inflammatory and metabolic disorders. Women show disproportionate increases in left ventricular filling pressures following increases in central blood volume and have greater arterial stiffness than men. Additionally, they are particularly predisposed to epicardial and intramyocardial fat expansion and imbalances in adipocyte-associated proinflammatory mediators. The hormonal interrelationships seen in inflammatory-metabolic phenotype may explain why mineralocorticoid receptor antagonists and neprilysin inhibitors may be more effective in women than in men with HFpEF. Recognition of the inflammatory-metabolic phenotype may improve an understanding of the pathogenesis of HFpEF and enhance the ability to design clinical trials of interventions in this heterogeneous syndrome.

show abstract

“…104,105 MR antagonism prevented diabetic neuropathy, as shown by improved motor-nerve conduction velocity and mean myelin area after 8 weeks of eplerenone treatment in streptozotocin-induced diabetic rats. 106…”

Section: Preclinical Data: Benefit Of Mr Blockade In Diabetic Nephropmentioning

confidence: 99%

Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis

Barrera‐Chimal

Girerd

Jaisser

2019

Kidney International

178

127

View full text Add to dashboard Cite

Protective effects of mineralocorticoid receptor blockade against neuropathy in experimental diabetic rats

Abstract: MR blockade may have neuroprotective effects on DPN.

Cited by 10 publications

References 52 publications

Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats

Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats

Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease

Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis

Contact Info

Product

Resources

About